

Ziv-aflibercept

Cat. No.:	HY-108798
CAS No.:	1609655-49-3
Target:	VEGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases ^{[1][2]} .								
In Vitro	<p>Ziv-aflibercept (0.25, 0.5, 1.0 and 5 mg/mL; 24 h) reduces mitochondrial membrane potential in ARPE-19 cells with dose dependent manner^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>ARPE-19 cells.</td> </tr> <tr> <td>Concentration:</td> <td>0.25, 0.5, 1.0 and 5 mg/mL.</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h.</td> </tr> <tr> <td>Result:</td> <td>Insignificantly affected cell viability (below 1 mg/mL).</td> </tr> </table>	Cell Line:	ARPE-19 cells.	Concentration:	0.25, 0.5, 1.0 and 5 mg/mL.	Incubation Time:	24 h.	Result:	Insignificantly affected cell viability (below 1 mg/mL).
Cell Line:	ARPE-19 cells.								
Concentration:	0.25, 0.5, 1.0 and 5 mg/mL.								
Incubation Time:	24 h.								
Result:	Insignificantly affected cell viability (below 1 mg/mL).								
In Vivo	<p>Ziv-aflibercept (25 mg/mL; intravitreal injection; single dose) insignificantly causes cataract, retinal detachment and other related complications in the right eye of the rabbit^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								

REFERENCES

- [1]. Malik D, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol. 2014 Jun;98 Suppl 1(Suppl 1):i11-16.
- [2]. de Oliveira Dias JR, et al. Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. Int J Retina Vitreous. 2016 Feb 1;2:3.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA